Unmet Medication Coverage Needs Among Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

December 21, 2017

This poster was presented at the 30th annual  Psych Congress, held Sept. 16-19, 2017, in New Orleans, Louisiana.

Background: Stimulant medications have been demonstrated effective in alleviating ADHD symptoms in adults. However, few studies have described the differing medication coverage needs of these patients. This study assessed unmet treatment needs related to duration among adults using various types of ADHD medications.

Methods: A cross-sectional online survey was conducted among adults with ADHD taking prescription medication ≥6 months. Respondents were stratified by current treatment: long-acting (LA) once daily; short-acting (SA) ≤twice daily; augmenters (AU), taking LA > once daily, LA plus SA, or SA > twice daily. Descriptive statistics were calculated for each survey question. Appropriate tests were used to compare responses by treatment subgroup.

Results: 616 patients (LA: 33%; SA: 27%; AU: 40%) completed the survey. Mean (SD) age was 39.0 (12.4); 70% were female. Self-reported ADHD severity and number of comorbidities were similar across groups. Overall, the afternoon (44%) was most commonly reported as the most difficult time of day. Respondents commonly noted that medication wearing-off negatively affected everyday life [work 250/510 (49%); school 190/356 (53%); household responsibilities 307/608 (50%); emotional responses/mood 235/603 (39%)]. Despite treatment, patients still experienced considerable burden from ADHD [home life (83% ≥1 impact); social life (76%); work 359/452 (79%); school 104/129 (81%)].

Conclusion: Even with medication, ADHD places considerable burden on adults. Optimizing treatment involves accounting for specific patient needs for coverage and considering individual differences in time of onset and duration of effect. These data may be useful to help clinicians optimize medication coverage for differing individual patient needs.

Disclosure: This study was supported by Shire Pharmaceuticals, Inc.

Authors: 
Thomas Brown, PhD; Emuella Flood, BA; Phil Sarocco, BPharm, MSc; Norman Atkins, Jr., MBA, PhD; Alexandra Khachatryan, MPH
Sponsoring Organization: 
Shire, LLC
Year: 
2017
Tracks: 
ADHD
Neurology/Neuroscience
PCN Topics: